Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations.
Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, EUROSPAN Consortium, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, ENGAGE Consortium, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo P, Salomaa V, Samani NJ, Schlessinger D, Uda M, Völker U, Waeber G, Waterworth D, Wang-Sattler R, Wright AF, Adamski J, Whitfield JB, Gyllensten U, Wilson JF, Rudan I, Pramstaller P, Watkins H, PROCARDIS Consortium, Doering A, Wichmann HE, KORA Study, Spector TD, Peltonen L, Völzke H, Nagaraja R, Vollenweider P, Caulfield M, WTCCC, Illig T, Gieger C. · 2009
Read Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. by Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, EUROSPAN Consortium, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, ENGAGE Consortium, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo P, Salomaa V, Samani NJ, Schlessinger D, Uda M, Völker U, Waeber G, Waterworth D, Wang-Sattler R, Wright AF, Adamski J, Whitfield JB, Gyllensten U, Wilson JF, Rudan I, Pramstaller P, Watkins H, PROCARDIS Consortium, Doering A, Wichmann HE, KORA Study, Spector TD, Peltonen L, Völzke H, Nagaraja R, Vollenweider P, Caulfield M, WTCCC, Illig T, Gieger C. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2683940.txt.
Introduction
Kolz and colleagues, working with the EUROSPAN Consortium and partner groups, merged genome scans from 28,141 Europeans in 2009 to find genes that set blood uric acid levels. High uric acid causes gout, a painful joint disease, and raises the risk of heart disease and diabetes. Fourteen studies pooled their data for this hunt.
Nine genome regions passed the strict bar for a real link, and five were entirely new. The strongest sat in SLC2A9, a gene for a sugar and urate transporter; its effect ran stronger in women. A second gene, ABCG2, pushed levels up more in men. One new region, SLC16A9, tied to two blood chemicals that themselves track uric acid, forming a three-way link that hints at a fresh control route. The finds map much of the inherited control of uric acid, and name targets for future gout drugs.
Catalog record
| CREATOR | Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, EUROSPAN Consortium, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, ENGAGE Consortium, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo P, Salomaa V, Samani NJ, Schlessinger D, Uda M, Völker U, Waeber G, Waterworth D, Wang-Sattler R, Wright AF, Adamski J, Whitfield JB, Gyllensten U, Wilson JF, Rudan I, Pramstaller P, Watkins H, PROCARDIS Consortium, Doering A, Wichmann HE, KORA Study, Spector TD, Peltonen L, Völzke H, Nagaraja R, Vollenweider P, Caulfield M, WTCCC, Illig T, Gieger C. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations By Melanie Kolz, Toby Johnson, Serena Sanna, Alexander Teumer, Veronique Vitart, Markus Perola, Massimo Mangino, Eva Albrecht, Chris Wallace, Martin Farrall, Åsa Johansson, Dale R Nyholt Published in: PLoS Genetics DOI: 10.1371/journal.pgen.1000504 ABSTRACT Abstract Elevated serum uric acid levels cause gout and are a risk factor for cardiovascular disease and diabetes. To investigate the polygenetic basis of serum uric acid levels, we conducted a meta-analysis of genome-wide association scans from 14 studies totalling 28,141 participants of European descent, resulting in identification of 954 SNPs distributed across nine loci that exceeded the threshold of genome-wide significance, five of which are novel. Overall, the common variants associated with serum uric acid levels fall in the following nine regions: SLC2A9 (p = 5.2×10−201), ABCG2 (p = 3.1×10−26), SLC17A1 (p = 3.0×10−14), SLC22A11 (p = 6.7×10−14), SLC22A12 (p = 2.0×10−9), SLC16A9 (p = 1.1×10−8), GCKR (p = 1.4×10−9), LRRC16A (p = 8.5×10−9), and near PDZK1 (p = 2.7×10−9). Identified variants were analyzed for gender differences. We found that the minor allele for rs734553 in SLC2A9 has greater influence in lowering uric acid levels in women and the minor allele of rs2231142 in ABCG2 elevates uric acid levels more strongly in men compared to women. To further characterize the identified variants, we analyzed their association with a panel of metabolites. rs12356193 within SLC16A9 was associated with DL-carnitine (p = 4.0×10−26) and propionyl-L-carnitine (p = 5.0×10−8) concentrations, which in turn were associated with serum UA levels (p = 1.4×10−57 and p = 8.1×10−54, respectively), forming a triangle between SNP, metabolites, and UA levels. Taken together, these associations highlight additional pathways that are important in the regulation of serum uric acid levels and point toward novel potential targets for pharmacological intervention to prevent or treat hyperuricemia. In addition, these findings strongly support the hypothesis that transport proteins are key in regulating serum uric acid levels. INTRODUCTION Uric acid (UA) is the final catabolic, heterocyclic purine derivative resulting from the oxidation of purines in humans. Due to the loss of hepatic uricase activity during human evolution, UA is excreted as such and is not further metabolized into carbon dioxide and ammonia. A major mechanism underlying hyperuricemia is impaired renal excretion of urate. Most notably, UA is causally involved in the pathogenesis of gouty arthritis that results from deposition of monosodium urate crystals in the joints [1]. Increased UA concentrations have been implicated in cardiovascular disease for more than five decades [2]. In addition, elevated urate is associated with obesity, blood pressure and insulin resistance, and consequently with the metabolic syndrome and type 2 diabetes [2],[3]. However, UA also has a positive role as an antioxidant, and is correlated with longevity in mammals [4]. Thus, human physiology is especially sensitive to the precise range of UA levels. Besides environmental factors, there is evidence for a strong genetic influence upon serum UA concentrations, with heritability estimates of up to 73% [5]. Recently, genome-wide association (GWA) studies have identified single nucleotide polymorphisms (SNPs) in the SLC2A9 gene (solute carrier family 2, member 9 gene), a putative glucose transporter, which are strongly associated with serum UA concentrations and gout [6]–[9]. This novel gene locus functions as a high-capacity urate transporter in humans [8],[10]. This emphasises the power of GWA studies in expanding our understanding at the molecular level of disease mechanisms and in pointing to innovative therapeutic strategies. The power of GWA studies to detect common variants with modest effects directly depends on the size of the study group. Therefore, the present study sought to detect novel genetic variants related to serum UA levels by conducting a meta-analysis of GWA findings from 14 studies (BRIGHT, CoLaus, CROATIA, Health 2000, KORA F3, KORA S4, ORCADES, PROCARDIS, NSPHS, SardiNIA, SHIP, SSAGA, MICROS, and TwinsUK) totalling 28,141 participants. In addition, the meta-analysis was performed independently on sex specific GWA results to address the pronounced gender differences in the regulation of UA concentrations that have previously been reported [1],[6]. Identified variants were further analyzed for association with metabolite profiles. RESULTS The sample size and participant characteristics for each participating study are shown in Table S1. Meta-analysis of GWA data of 28,141 individuals of European ancestry yielded 954 SNPs (full list is provided in Table S4) that exceeded the genome-wide significance threshold of 5×10−8 (Figure 1A). [Figure: Genome-wide association results.Manhattan plots showing significance of association of all SNPs in the meta-analysis for (A) men and women combined, (B) men only, and (C) women only. SNPs are plotted on the x-axis according to their position on each chromosome against association with uric acid concentrations on the y-axis (shown as −log10 p-value).] Those SNPs cluster around nine loci (Table 1), four of which are well known regulators of serum UA levels: SLC2A9 (p = 5.2×10−201), ABCG2 (p = 3.1×10−26), SLC17A1 (p = 3.0×10−14), and SLC22A12 (p = 2.0×10−9). The first, SLC2A9, was identified in previous GWA scans (Figure 2C) [6]–[9]. A total of 788 SNPs reached the genome-wide significance threshold at the SLC2A9 locus. The strongest associated marker was the intronic SNP rs734553 (p = 5.2×10−201, Table 1), which is in high linkage disequilibrium (r2 = 0.88) with the missense mutation rs16890979 previously described [11]. The second locus was on chromosome 4q22, harbouring the ABCG2 gene (Figure 2D). In accordance with previous results, the strongest observed association was at rs2231142 (p = 3.1×10−26, Table 1), a coding SNP leading to a glutamine-to-lysine amino acid change at position 141 [11]. The third previously implicated locus influencing UA levels was on chromosome 6p23-p21.3, which contains the SLC17A3 gene (Figure 2F) [11]. The top associated marker was SNP rs1183201 (p = 3.0×10−14, Table 1), intronic of SLC17A1, but the association signal encompassed a larger region including the SLC17A1, SLC17A3, SLC17A4 genes and downstream to HIST1H4C, in agreement with the linkage disequilibrium at this locus. SNP rs1183201 is in high linkage disequilibrium (r2 = 0.97) with rs1165205, a SNP intronic of SLC17A3 gene identified by a previous GWA scan [11]. [Table: Nine loci associated with uric acid concentrations.] [Figure: Regional association plots of nine urate loci.P-value plots showing the association signals in the region of (A) PDZK1 on chromosome 1, (B) GCKR on chromosome 2, (C) SLC2A9 on chromosome 4, (D) ABCG2 on chromosome 4, (E) LRRC16A on chromosome 6, (F) SLC17A1 on chromosome 6, (G) SLC16A9 on chromosome 10, (H) SLC22A11 on chromosome 11, and (I) SLC22A12 on chromosome 11. −log10 p-values are plotted as a function of genomic position (NCBI Build 36). Large diamonds in red indicate the most significant SNP in the region while other SNPs in the region are given as colour-coded smaller diamonds. Red diamonds indicate high correlation with the lead SNP (r2>0.8), orange diamonds indicate moderate correlation with the most significant SNP (0.5<r2<0.8), yellow indicates markers in weak correlation with the most significant SNP (0.2<r2<0.5), white indicates no correlation with the most significant SNP (r2<0.2). Estimated recombination rates (HapMap Phase II) are given in light blue, genes as well as the direction of transcription (NCBI) are displayed by green bars.] Among the novel loci identified, the strongest was on chromosome 11q13. One locus was localized upstream and within the SLC22A11 gene,